Strategic Stocks To Watch CORD BLOOD AMERICA INCORPORATED (OTCBB: CBAI)
Up 78.57% on Monday
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
CBAI News:
January 9 – Advanced Cell Technology and Cord Blood America (CBAI) Poised for Growth in 2012
01-10-12 Strategic Stocks To Watch CORD BLOOD AMERICA INCORPORATED (OTCBB: CBAI)
The Paragon Report Provides Equity Research on Advanced Cell Technology & Cord Blood America
Stem Cell stocks — particularly companies focused on adult stems cells — have performed well of late. Earlier this month Goldman Sachs noted the potential upside of Pluristem Therapeutics — noting that the company does not use the highly controversial embryonic stem cells. The remark from the analyst firm helped drive shares of similar companies that use adult stem cells. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Advanced Cell Technology, Inc. (OTCBB: ACTC) and Cord Blood America, Inc. (OTCBB: CBAI).
Access to the full company reports can be found at:
www.paragonreport.com/ACTC
www.paragonreport.com/CBAI
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. In late December, the company announced that it signed an exclusive agreement to store stem cells at its Las Vegas laboratory for the National Children’s Leukemia Foundation (NCLF), New York.
Cord blood stem cells are presently used to treat 75 diseases including leukemia, severe anemia, metabolic blood disorders and immune deficiencies, with ongoing research worldwide to treat many of the world’s most serious diseases, including diabetes, heart disease and stroke.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Advanced Cell Technology, Inc. applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine. In a recent “blog from the chairman” on the company’s website, Gary Rabin observes that Advanced Cell Technology now has the distinction of being the only company that is conducting FDA-cleared human clinical trials using human embryonic stem cell-derived therapies. “Both of our ongoing Phase 1/2 trials use human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells, one for Stargardt’s macular dystrophy (SMD) and the other for dry age-related macular degeneration (dry AMD),” Rabin explains
If you find our information valuable, Subscribe to Strategic Stocks and Penny Stocks RSS Feed by e-mail, to Receive our Updates INSTANTLY, and share this post/page with your friends and followers with use of the Social Buttons.
Like all investment strategies, trading in stocks involves risk and volatility. Past performance is not an indication of future results. Actual results will be based on a consumer’s individual purchase and sale decisions.
Please read our Disclaimer regards to CBAI or any company reviewed or blogged about at Strategic Penny Stocks.
